1. Ironwood axes GERD hopeful, plans staff layoffs — JAMA study shows older adults being excluded from many COVID trials — FDA fast tracks AbbVie's spinal injury drug — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice
Latest trending news COVID-19 and your job

Fallout

Discussion in 'Dendrite' started by Anonymous, Oct 10, 2012 at 3:17 PM.

Tags: Add Tags
  1. #1 Anonymous, Oct 10, 2012 at 3:17 PM
    Anonymous

    Anonymous Guest

    Heard there was bleeding occurring - what happened?
     
    Quote

  2. #2 Anonymous, Oct 16, 2012 at 3:02 PM
    Anonymous

    Anonymous Guest

    The DoucheBags who bought Dendrite for SEVEN HUNDRED FIFTY MILLION DOLLARS did not have the foresight to understand this product type was in the tail of it's product life cycle. This, coupled with the Pharma consolidations, R&D pipeline failures and patent cliffs do not make a Pharma CRM vendor so 'special' anymore. Customers are looking at Veeva as the leader in this narrow sector. Growth is not possible for now and unless they build some new compelling product, this shoppe will continue to just cut costs to survive. Doesnt look too promising.
     
    Quote
Reply to Thread